Wednesday, July 8, 2026

Drug profile · INN

berdazimer sodium

berdazimer sodium (ZELSUVMI) is a releases no, antimicrobial. Route of administration: topical. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — berdazimer sodium
US status
approved
Class
Route
TOPICAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

berdazimer sodium (ZELSUVMI) is a releases no, antimicrobial. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN berdazimer sodium
Brand ZELSUVMI
Mechanism Releases NO, antimicrobial
Route TOPICAL
Formulation GEL

Mechanism of action

Releases NO, antimicrobial

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Zimberelimab (ZIM) Phase 2 · Arcus Biosciences · Lung Cancer

Frequently asked questions

What is berdazimer sodium?

berdazimer sodium (ZELSUVMI) is a releases no, antimicrobial. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for berdazimer sodium?

ZELSUVMI is a marketed brand name for berdazimer sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of berdazimer sodium?

berdazimer sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.